Stock Movers: Eli Lilly, CarMax, and Jabil Stock Performance After Earnings

Eli Lilly's Experimental Drug Study Halted

• 💡 Eli Lilly (LLY) shares experienced a modest decline of about 1%, underperforming the S&P 500.
• ⚠️ The company halted a study of an experimental drug intended to prevent muscle loss in obese patients undergoing weight loss treatment.
• 💬 A spokesperson cited regular re-evaluation of drug trials as the reason, though analysts found the decision somewhat surprising.

CarMax Faces Significant Earnings Miss

• 📉 CarMax (KMX) was the worst performer in the S&P 500, with shares falling significantly after a substantial earnings per share and sales shortfall for the second quarter.
• 🎯 Truist Financial Services described the results as a "miss across the board with nothing good to see here."
• 📉 Wedbush downgraded the stock to neutral, and the shares are trading at their lowest level since March 2020.
• 🚗 Weaker trends in used car sales are reported to have continued into the current quarter.

Jabil's Margin Pressure and Stock Performance

• 📊 Jabil (JBL) shares fell approximately 7%, making it the second-worst performer after reporting results that mostly missed analyst expectations.
• ⚡ Vital Knowledge highlighted pressure on margins within Jabil's AI-exposed Intelligent Infrastructure segment.
• 📈 Despite the daily drop, the stock has seen significant gains over the past year, and its first-quarter forecast for net revenue and core EPS was better than expected.

Broader Market and Auto Sector Concerns

• 🚗 The auto sector is generally performing poorly, with companies like Ford, Tesla, and General Motors facing challenges.
• 🇩🇪 Robert Bosch is cutting approximately 13,000 jobs in Germany due to a sluggish European car market.
• 📈 Despite these sector-specific issues, broader markets are trading near all-time highs.